USFDA issues three observations post inspection of Ipca Lab's Silvassa unit

In a regulatory filing to BSE, Ipca Laboratories said the USFDA had conducted the inspection of the its formulations manufacturing unit situated at Piparia (Silvassa) from August 19 - 23.

  • Published On Aug 24, 2019 at 04:47 PM IST
Read by: 100 Industry Professionals
Reader Image Read by 100 Industry Professionals
New Delhi: Drug firm Ipca Laboratories on Saturday said the US Food and Drug Administration (FDA) has conducted an inspection of its formulations manufacturing unit in Silvassa and issued three observations. In a regulatory filing to BSE, Ipca Laboratories said the USFDA had conducted the inspection of the its formulations manufacturing unit situated at Piparia (Silvassa) from August 19 - 23.

"At the conclusion of the inspection, the US FDA issued a Form 483 with 3 (three) observations. The company shall be submitting its comprehensive response on these observations to the US FDA within the stipulated time frame," it added.

Advt
The company said it is committed to address these observations promptly.

The US health regulator issues observations by means of Form 483 notifying the company's management of objectionable conditions at the facility inspected.
  • Published On Aug 24, 2019 at 04:47 PM IST
Be the first one to comment.
Comment Now

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles
Scan to download App